MetLife Investment Management LLC Decreases Position in Maximus, Inc. $MMS

Key Points

• MetLife Investment Management LLC has reduced its stake in Maximus, Inc. by 7.4%, bringing its total holdings to 63,627 shares valued at approximately $4.34 million.
• New ratings for Maximus include a shift from a "hold" to a "strong-buy" by Zacks Research, while the consensus target price stands at $90.00.
• Maximus recently announced a quarterly dividend of $0.30 per share, translating to an annualized yield of 1.4% based on its current payout ratio of 22.10%.

MetLife Investment Management LLC lowered its stake in shares of Maximus, Inc. (NYSE:MMS - Free Report) by 7.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 63,627 shares of the health services provider's stock after selling 5,062 shares during the period. MetLife Investment Management LLC owned 0.11% of Maximus worth $4,339,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its stake in Maximus by 17,533.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 529 shares of the health services provider's stock valued at $36,000 after buying an additional 526 shares in the last quarter. UMB Bank n.a. grew its stake in Maximus by 70.2% in the 1st quarter. UMB Bank n.a. now owns 606 shares of the health services provider's stock valued at $41,000 after buying an additional 250 shares in the last quarter. GAMMA Investing LLC grew its stake in Maximus by 67.1% in the 1st quarter. GAMMA Investing LLC now owns 732 shares of the health services provider's stock valued at $50,000 after buying an additional 294 shares in the last quarter. NBC Securities Inc. grew its stake in Maximus by 114,900.0% in the 1st quarter. NBC Securities Inc. now owns 1,150 shares of the health services provider's stock valued at $78,000 after buying an additional 1,149 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in Maximus by 32.8% in the 1st quarter. Blue Trust Inc. now owns 1,228 shares of the health services provider's stock valued at $84,000 after purchasing an additional 303 shares during the period. 97.21% of the stock is currently owned by hedge funds and other institutional investors.

Maximus Price Performance

Shares of NYSE MMS traded up $1.53 during mid-day trading on Tuesday, reaching $89.45. 621,151 shares of the company were exchanged, compared to its average volume of 571,356. Maximus, Inc. has a 52 week low of $63.77 and a 52 week high of $93.94. The company has a quick ratio of 2.27, a current ratio of 2.27 and a debt-to-equity ratio of 0.91. The stock has a market capitalization of $5.04 billion, a PE ratio of 16.47 and a beta of 0.61. The company's 50 day moving average price is $76.74 and its 200 day moving average price is $71.85.

Maximus (NYSE:MMS - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The health services provider reported $2.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.39 by $0.77. Maximus had a net margin of 5.83% and a return on equity of 24.44%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the previous year, the firm posted $1.74 EPS. The firm's revenue was up 2.5% compared to the same quarter last year. Maximus has set its FY 2025 guidance at 7.350-7.550 EPS. Sell-side analysts forecast that Maximus, Inc. will post 6.15 earnings per share for the current fiscal year.

Maximus Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Sunday, August 31st. Stockholders of record on Friday, August 15th were issued a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend was Friday, August 15th. Maximus's payout ratio is currently 22.10%.

Wall Street Analysts Forecast Growth

MMS has been the subject of several analyst reports. Zacks Research raised shares of Maximus from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 26th. Wall Street Zen downgraded shares of Maximus from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Strong Buy" and a consensus target price of $90.00.

Maximus Company Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.